Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10370 in Advanced Solid Tumors
NCT05367778Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hs-10370 in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate up to 24 months. Started Jun 2022; status: recruiting.
02
Drugs
hs-10370
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05367778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367778.